Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150

Merck & Co., Inc. (NYSE:MRK | MRK Price Prediction) has been on a strong recovery run, gaining 23% over the past year and 8% year-to-date, though the stock has pulled back some, now well below its 52-week high of $125.14. Most analysts hold measured views, with Street consensus sitting at $127.22. But Wells Fargo sees considerably more upside, raising its price target to $150 from $135 with an Overweight rating, implying meaningful upside from current levels. That target stands well above the Street average. But can MRK realistically reach $150 by the end of 2026?

Wells Fargo’s $150 MRK Prediction

Wells Fargo’s bull case centers on sacituzumab tirumotecan, or sac-TMT, Merck’s investigational anti-TROP2 antibody-drug conjugate. The firm believes sac-TMT could become the best-in-class TROP2 ADC and replace chemotherapy across multiple lung, breast, and gynecologic cancer indications. That thesis gets tangible support from the FDA, which awarded sac-TMT a Commissioner’s National Priority Voucher, and from a strategic financing agreement with Blackstone Life Sciences to partially fund sac-TMT development.

Key Drivers of MRK Stock Performance

1. Sac-TMT pipeline value: Sac-TMT’s potential to displace chemo in lung, breast, and gynecologic cancers represents a multi-indication commercial opportunity that could meaningfully expand Merck’s oncology franchise well into the next decade, representing a multi-indication commercial opportunity that could meaningfully expand Merck’s oncology franchise well into the next decade.
2. KEYTRUDA’s continued expansion: The flagship immunotherapy posted $8.337 billion in Q4 2025 revenue, up 6% year-over-year, with the FDA also accepting two sBLAs for KEYTRUDA plus Trodelvy in first-line PD-L1+ metastatic triple-negative breast cancer. Expanding indications extend KEYTRUDA’s revenue runway despite the 2028 patent cliff.
3. Emerging growth portfolio: WINREVAIR, Merck’s pulmonary arterial hypertension treatment, delivered $467 million in Q4 2025, up 133% year-over-year, while a commitment of more than $70 billion in U.S. capital and R&D spending signals management’s conviction in long-term compounding power for shareholders.

What Will It Take for MRK to Reach $150?

At approximately 2.48 billion shares outstanding, a $150 price would imply a market capitalization well above today’s market cap near $283.4 billion. Getting there requires three things: positive late-stage data or regulatory progress for sac-TMT establishing its best-in-class profile, continued KEYTRUDA growth sustaining investor confidence through the patent cliff transition, and normalization of FY2026 EPS optics once the ~$3.65 per share one-time Cidara acquisition charge clears.

The primary risk is the KEYTRUDA patent cliff, which represents roughly half of pharmaceutical revenues, with biosimilar competition looming in 2028. Still, with sac-TMT’s best-in-class TROP2 potential and a deepening pipeline of approximately 80 Phase 3 studies underway, Wells Fargo’s $150 target reflects a credible, pipeline-driven rerating thesis supported by sac-TMT’s best-in-class TROP2 potential and a deepening pipeline of approximately 80 Phase 3 studies underway.